A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects

• Main Authors: Akira Utsunomiya (Author), Noritaka Oyama (Author), Shiro Iino (Author), Natsuki Baba (Author), Takenao Chino (Author), Natsuko Utsunomiya (Author), Minoru Hasegawa (Author)
• Format: Book
• Published: Karger Publishers, 2018-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Immune checkpoint inhibitors, such as ipilimumab and nivolumab, reverse the imbalance of antitumor self-tolerance and enhance T-cell responses. Currently, ipilimumab and nivolumab have a reported therapeutic impact on unresectable or metastatic melanomas; however, they also induce immune-related adv...